Apparatus and method for identifying one or more amyloid beta plaques in a plurality of discrete OCT retinal layers

1. A system to produce an image of an eye of a patient to identify at least one amyloid beta plaque and amyloid containing drusen in a plurality of discrete retinal layers, comprising:

an (optical coherence tomography) OCT system for obtaining an amyloid beta plaque image, an amyloid image or an amyloid beta peptide image that resides within said discrete retinal layers having a spectral signature;

a computer system that processes data and controls said apparatus that is in communication with said OCT system, wherein said computer system is a compact computer;

at least one contrast agent, selected from the group consisting of curcumin, curcumin derivatives, Thioflavin S, Thioflavin derivatives, Thioflavin T, Thioflavin T derivatives, Congo Red, one or more Congo Red derivatives, methoxy-X04, Pittsburgh Compound S (PiB), DDNP and Chrysamine-G;

wherein said system includes at least one component selected from the group consisting of a mercury arc lamp, a variable wavelength light source, a xenon arc lamp, an LED light source, a tunable light source or swept source, and an acoustic-optic tunable filter-based spectral image acquisition system

wherein said apparatus performs a maximum and a minimum intensity projection to define a volume of interest of a specific region of interest and said discrete retinal layers, to obtain different images of plaque and drusen to thereby provide plaque and drusen differentiation.

2. A method for identifying one or more amyloid beta plaques and amyloid containing drusen in a plurality of discrete OCT retinal layers, comprising the steps of:

identifying one or more A(beta) peptides located above a retinal pigment epithelium thereby differentiating said one or more A(beta) peptides from said drusen;

imaging a mammal's retina with an OCT system and a multispectral and a hyperspectral imaging or an Autofluorescence imaging device;

examining said images of said A(beta) peptides; and quantifying an increase or a decrease of said A(beta) peptides in said mammal's retina.

3. The method according to claim 2 , further comprising evaluating one or more discrete locations of said one or more plaques in said one or more discreet locations of said one or more retinal layers, above said retinal pigment epithelium, as differentiated from said drusen which reside in or below said retinal pigment epithelium.

4. A method for staining one or more amyloid beta plaques and amyloid containing drusen in a plurality of discrete OCT retinal layers with a normative database, comprising the steps of:

administering and staining a plurality of A(beta) peptides with a contrasting agent;

imaging said mammal's retina with an OCT system by identification of a spectral signature and retinal layer segmentation of amyloid in an OCT data set or one or more modalities;

examining said images of said stained A(beta) peptides;

quantifying an increase or a decrease of said stained A(beta) peptides in said mammal's retina.

5. The method according to claim 4 , wherein said one or more modalities include varying one or more wavelengths of said OCT system and analyzing a generated signal to derive an amyloid signal.

6. The method according to claim 4 , wherein said signals are generated with said OCT system and a multispectral confocal and one or more optical imaging techniques.

7. The method according to claim 4 , wherein said signals are generated with one or more image and OCT layer segmentation techniques.

8. The method according to claim 4 , wherein said signals are generated from said one or more optical imaging techniques exclusively using said one or more wavelengths.

9. The method according to claim 4 , wherein said signals are generated from an exclusive OCT identification of deposit and layer segmentation.

10. The method according to claim 4 , wherein said signals are generated from an exclusive hyperspectral imaging.

11. The method according to claim 4 , wherein said signals are generated from exclusive multi-spectral imaging.

12. The method according to claim 4 , wherein said signals are generated from autofluorescence.

13. The method according to claim 4 , wherein said spectral signature of said amyloid is obtained by spectral analysis and image processing.

14. The method according to claim 4 , wherein said OCT data set is compared to one or more other OCT data sets in said normative database and a subsequent disease state and a subsequent normal state is determined based on a comparison of said normative database and a location within said retina compared with one or more other disease states.